The Miriam Hospital Immunology Center: drugs
Schedule G of this filing lists 13 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 13drugs listed
- $2,859,268.09 (Schedule G, printed total, page 10 of the filing PDF)Total as filed
- 2,299 (Schedule G, printed claims total, page 10 of the filing PDF)Claims total as filed
- 4rows show “fewer than 6” for claims. What this means
All 13 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | Mavyret 100/40 mg tab 8400074262528Listed by the FDA as Mavyretglecaprevir and pibrentasvir40 mg; 100 mgtablet, film coatedAbbVie Inc. | 187,047.21 (Schedule G, line 1, page 10 of the filing PDF) | 22 |
| 2 | Tivicay 50 mg tab 3049702022813Listed by the FDA as Tivicaydolutegravir sodium50 mgtablet, film coatedViiV Healthcare Company | 11,171.42 (Schedule G, line 2, page 10 of the filing PDF) | 6 |
| 3 | Cabenuva 600-900 mg sus kit49702024015Listed by the FDA as Cabenuvacabotegravir and rilpivirinekitViiV Healthcare Company | 5,044.77 (Schedule G, line 3, page 10 of the filing PDF) | 0 |
| 4 | Dovato 50 mg-300 mg tab 3049702024613Listed by the FDA as Dovatodolutegravir sodium and lamivudine50 mg; 300 mgtablet, film coatedViiV Healthcare Company | 10,078.38 (Schedule G, line 4, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 5 | Apretude 600 mg kit49702026423Listed by the FDA as ApretudecabotegravirkitViiV Healthcare Company | 1,285,350.78 (Schedule G, line 5, page 10 of the filing PDF) | 419 |
| 6 | Harvoni 90 mg/400 mg tab 2861958180101Listed by the FDA as Harvoniledipasvir and sofosbuvir90 mg; 400 mgtablet, film coatedGilead Sciences, Inc | 6,485.78 (Schedule G, line 6, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 7 | Descovy 200-25 mg tab 3061958200201Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 1,055,345.28 (Schedule G, line 7, page 10 of the filing PDF) | 994 |
| 8 | Descovy 200 mg-25 mg tab 30 UD61958200202Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 8,762.95 (Schedule G, line 8, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 9 | Epclusa 400/100 mg tab 2861958220101Listed by the FDA as Epclusavelpatasvir and sofosbuvir100 mg; 400 mgtablet, film coatedGilead Sciences, Inc. | 47,134.64 (Schedule G, line 9, page 10 of the filing PDF) | 9 |
| 10 | Biktarvy 50 mg/200 mg/25 mg tab 3061958250101Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 24,266.40 (Schedule G, line 10, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 11 | Yeztugo 300 mg tab 461958340101Listed by the FDA as Yeztugolenacapavir sodium300 mgtablet, film coatedGilead Sciences, Inc. | 19,841.58 (Schedule G, line 11, page 10 of the filing PDF) | 11 |
| 12 | Yeztugo 463.5 mg SDV 2x1.5 mL61958340201Listed by the FDA as Yeztugolenacapavir sodiumkitGilead Sciences, Inc. | 119,049.70 (Schedule G, line 12, page 10 of the filing PDF) | 11 |
| 13 | Sofosbuvir Velpatasvr 400 mg-100 mg tab 2872626270101Listed by the FDA as Sofosbuvir and Velpatasvirvelpatasvir and sofosbuvir100 mg; 400 mgtablet, film coatedAsegua Therapeutics LLC | 66,655.91 (Schedule G, line 13, page 10 of the filing PDF) | 13 |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 13,033.29 (Schedule G, row for amounts under $5,000, page 10 of the filing PDF) | 799 (Schedule G, claims on the row for amounts under $5,000, page 10 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement | 2,859,268.09 (Schedule G, printed total, page 10 of the filing PDF) | 2,299 (Schedule G, printed claims total, page 10 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. All 13 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- d4c0df0984ca3b085be4730079ed2ee9f8de00ca725ead684a19892c9712242e
- Retrieved
- 11 November 2026
- Pages used
- 10 of 13